Pharmaceuticals, Biotechnology and Life Sciences
Company announcement – No. 21/ 2021 Boehringer Ingelheim and Zealand Pharma Advance to Phase 2 Clinical Testing in NASH and…
J&J has answered allegations about its batch of vaccines that could not be used after ingredient issues.
EMA’s human medicines committee (CHMP) has adopted several important recommendations that will increase manufacturing capacity and supply of COVID-19 vaccines…
GSK has reached an agreement in principle with Novavax and the UK Government Vaccines Taskforce to support manufacturing of up…
The U.S. Food and Drug Administration approved a new indication for Astellas Pharma’s Myrbetriq (mirabegron extended-release tablets) and Myrbetriq Granules (mirabegron for extended-release oral suspension) to treat neurogenic detrusor overactivity (NDO), a bladder dysfunction related to neurological impairment, in children ages three years and older.
AstraZeneca has issued a statement to clarify a number of inaccurate statements relating to COVID-19 Vaccine AstraZeneca doses at the Anagni plant in Italy.
AstraZeneca’s AZD1222 got positive high-level results from the primary analysis of the Phase III trial which in the US have confirmed vaccine efficacy consistent with the pre-specified interim analysis announced on Monday 22 March 2021.
Novadiscovery has entered into a new collaboration with Takeda Pharmaceutical Company Limited (“Takeda”) aimed at incorporating clinical simulation technology on virtual patients into Takeda France’s access strategy.
AstraZeneca has denied accusations of stockpiling vaccines stating that the process of manufacturing vaccines is very complex and time consuming…
Novo Nordisk’a new results from the STEP phase 3a clinical trial programme showed weight loss with investigational treatment of once-weekly subcutaneous semaglutide 2.4 mg versus placebo.